Cytosorbents Corp (CTSO) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Cytosorbents Corp's filing signal continuing negative.

Cytosorbents Corporation is a leader in treating life-threatening conditions in intensive care and cardiac surgery through its proprietary blood purification technology. This technology utilizes biocompatible polymer beads to remove toxic substances from blood via pore capture and surface adsorption, compatible with standard hospital blood pumps. The company's lead product, CytoSorb, is approved in the European Union and distributed in over 70 countries, targeting the removal of cytokines and inflammatory agents in critical illnesses like sepsis and ARDS, as well as blood thinners in cardiothoracic surgery. In the U.S., the company is developing DrugSorb-ATR for antithrombotic removal, which has received FDA Breakthrough Device Designations for ticagrelor and DOAC removal. CytoSorbents also offers VetResQ for animal health in the U.S. and the PuriFi hemoperfusion pump internationally.

Revenue is primarily driven by the sale of its CytoSorb blood purification cartridges, with additional revenue from VetResQ for animal health and the PuriFi pump. Sales are generated through direct sales forces and a network of distributors and strategic partners across more than 70 countries.